Cargando…

Safety and Efficacy of Dupilumab for the Treatment of Hospitalized Patients With Moderate to Severe Coronavirus Disease 2019: A Phase 2a Trial

BACKGROUND: Based on studies implicating the type 2 cytokine interleukin 13 (IL-13) as a potential contributor to critical coronavirus disease 2019 (COVID-19), this trial was designed as an early phase 2 study to assess dupilumab, a monoclonal antibody that blocks IL-13 and interleukin 4 signaling,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sasson, Jennifer, Donlan, Alexandra N, Ma, Jennie Z, Haughey, Heather M, Coleman, Rachael, Nayak, Uma, Mathers, Amy J, Laverdure, Sylvain, Dewar, Robin, Jackson, Patrick E H, Heysell, Scott K, Sturek, Jeffrey M, Petri, William A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9361171/ https://www.ncbi.nlm.nih.gov/pubmed/35959207 http://dx.doi.org/10.1093/ofid/ofac343

Ejemplares similares

Safety and Efficacy of Dupilumab for the Treatment of Hospitalized Patients with Moderate to Severe COVID 19: A Phase IIa Trial
por: Sasson, Jennifer, et al.
Publicado: (2022)

Pulmonary function and survival one year after dupilumab treatment of acute moderate to severe COVID-19: A follow up study from a Phase IIa trial
por: Hendrick, Jennifer, et al.
Publicado: (2023)

Dupilumab Use Is Associated With Protection From Coronavirus Disease 2019 Mortality: A Retrospective Analysis
por: Donlan, Alexandra N, et al.
Publicado: (2022)

Community-Acquired Pneumonia in Canada During Coronavirus Disease 2019
por: Mandell, Lionel A, et al.
Publicado: (2022)

Clostridioides difficile Binary Toxin Binding Component Increases Virulence in a Hamster Model
por: Simpson, Morgan, et al.
Publicado: (2023)

A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019
por: Kim, Jin Yong, et al.
Publicado: (2022)

Tuberculosis Disease Among Adults Aged 65 Years and Older: Alameda County, California, 2016–2019
por: Wu, Iris L, et al.
Publicado: (2022)

Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid
por: Zhang, Yihua, et al.
Publicado: (2021)

Safety and Efficacy of Tocilizumab 4 or 8 mg/kg in Hospitalized Patients With Moderate to Severe Coronavirus Disease 2019 Pneumonia: A Randomized Clinical Trial
por: Kumar, Princy N, et al.
Publicado: (2021)

Using a multimodal strategy to improve patient hand hygiene
por: Loveday, Heather P., et al.
Publicado: (2021)

Randomized Study of Rivaroxaban vs Placebo on Disease Progression and Symptoms Resolution in High-Risk Adults With Mild Coronavirus Disease 2019
por: Ananworanich, Jintanat, et al.
Publicado: (2021)

Efficacy and Safety of Ensitrelvir in Patients With Mild-to-Moderate Coronavirus Disease 2019: The Phase 2b Part of a Randomized, Placebo-Controlled, Phase 2/3 Study
por: Mukae, Hiroshi, et al.
Publicado: (2022)

Evaluation of K18-hACE2 Mice as a Model of SARS-CoV-2 Infection
por: Moreau, Gregory Brett, et al.
Publicado: (2020)

Testing for Cryptococcosis at a Major Commercial Laboratory—United States, 2019–2021
por: Benedict, Kaitlin, et al.
Publicado: (2022)

Reducing Repeat Blood Cultures in Febrile Neutropenia: A Single-Center Experience
por: Robinson, Evan D, et al.
Publicado: (2022)

Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients With Mild-to-Moderate Coronavirus Disease 2019
por: Streinu-Cercel, Anca, et al.
Publicado: (2022)

Coronavirus Disease 2019–Associated Invasive Fungal Infection
por: Baddley, John W, et al.
Publicado: (2021)

Retrospective Study of Dupilumab Treatment for Moderate to Severe Atopic Dermatitis in Korea: Efficacy and Safety of Dupilumab in Real-World Practice
por: Jang, Dong Hyek, et al.
Publicado: (2020)

Dupilumab in the management of moderate-to-severe asthma: the data so far
por: Barranco, Pilar, et al.
Publicado: (2017)

Dupilumab in the Treatment of Moderate to Severe Asthma: An Evidence-Based Review
por: Rathinam, Kiran Kumar, et al.
Publicado: (2019)

Commentary: Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid
por: Wang, Si-Hang, et al.
Publicado: (2021)

Dupilumab in patients with moderate to severe atopic dermatitis and multiple sclerosis
por: Esposito, Maria, et al.
Publicado: (2022)

Increased Fecal Lactobacillus Is Associated With a Positive Glucose Hydrogen Breath Test in Bangladeshi Children
por: Donowitz, Jeffrey R, et al.
Publicado: (2019)

Facilitating Safe Discharge Through Predicting Disease Progression in Moderate Coronavirus Disease 2019 (COVID-19): A Prospective Cohort Study to Develop and Validate a Clinical Prediction Model in Resource-Limited Settings
por: Chandna, Arjun, et al.
Publicado: (2022)

Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults
por: Xu, Xinghua, et al.
Publicado: (2017)

Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults
por: Kuznik, Andreas, et al.
Publicado: (2017)

Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma
por: Castro, Mario, et al.
Publicado: (2020)

Maternal Mortality in Brazil, 1990 to 2019: a systematic analysis of the Global Burden of Disease Study 2019
por: Leal, Lisiane Freitas, et al.
Publicado: (2022)

Coronavirus Disease 2019–Associated Pulmonary Aspergillosis: A Noninvasive Screening Model for Additional Diagnostics
por: Permpalung, Nitipong, et al.
Publicado: (2023)

Projected Long-Term Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on Hepatitis C Outcomes in the United States: A Modeling Study
por: Barocas, Joshua A, et al.
Publicado: (2021)

Dupilumab Efficacy in Patients with Uncontrolled Moderate-to-Severe Type 2 Asthma Regardless of Perennial Aeroallergen Sensitization
por: Corren, Jonathan, et al.
Publicado: (2023)

Etiology of Fever and Associated Outcomes Among Adults Receiving Chemotherapy for the Treatment of Solid Tumors in Uganda
por: Gulleen, Elizabeth A, et al.
Publicado: (2023)

The increasing burden of pancreatic cancer in Brazil from 2000 to 2019: estimates from the Global Burden of Disease Study 2019.
por: Chaves, Diogo Oliveira, et al.
Publicado: (2022)

Dying at Home Due to Coronavirus Disease 2019
por: Edwards, Jessie K, et al.
Publicado: (2022)

Virological and Serological Assessment of US Army Trainees Isolated for Coronavirus Disease 2019
por: Hakre, Shilpa, et al.
Publicado: (2022)

Burden of non-communicable diseases attributable to dietary risks in Brazil, 1990-2019: an analysis of the Global Burden of Disease Study 2019
por: Machado, Ísis Eloah, et al.
Publicado: (2022)

Suicide mortality among older adults in Brazil between 2000 and 2019 - estimates from the Global Burden of Disease Study 2019
por: Pires, Ademar Moreira, et al.
Publicado: (2022)

Clinical Yield of a Molecular Diagnostic Panel for Enteric Pathogens in Adult Outpatients With Diarrhea and Validation of Guidelines-Based Criteria for Testing
por: Clark, Stephen D, et al.
Publicado: (2019)

Dupilumab maintenance therapy in an asthmatic patient with coronavirus disease 2019 pneumonia
por: Tanabe, Naoya, et al.
Publicado: (2021)

Trend of the Burden of Larynx Cancer in Brazil, 1990 to 2019
por: Viana, Luciana de Paula, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7i2j7tqqem2t3todrqli6in5o3